The First Medical Cannabis Dispensary in Virginia has Opened its Doors
October 21st, 2020
News, Top News
Dharma Pharmaceuticals, the first medical cannabis dispensary in Virginia, has opened its doors. Dharma Pharmaceuticals is one of four licensed medical cannabis companies in the Commonwealth of Virginia. Located in Bristol, the company’s mission is to provide patients with high-quality, safe and effective plant-based medicines, all while bringing crucial jobs to an economically distressed area.
“We are eager to provide a new treatment option to Virginia patients and also provide jobs and economic growth within our community,” says Dharma Pharmaceuticals Co-Founder and CEO, Shanna Berry. “This has been a long process to build out a facility, grow cannabis plants from seed, process and extract the cannabis oils, and finally have product ready for patients. As a lifelong resident of Southwest Virginia, I am thrilled to bring this life-changing medicine to our state and provide much needed jobs in our community.” Berry has waited ten years for the climate in Virginia to shift to allow for medical cannabis and the start of Dharma Pharmaceuticals.
Berry is joined by Co-Founder and Chief Operating Officer, Jack L. Page and Co-Founder and Chief Pharmacy Officer, Michael Johnson. Johnson, who has 27 years of Virginia pharmacy experience, is thrilled to finally serve patients, saying “Each patient seeking medical cannabis is unique, and I look forward to cultivating relationships with them to develop treatment plans customized for their individual needs.” Page says, “Dharma Pharmaceuticals is truly a homegrown effort led by local business professionals with a passion for our community and helping patients gain access to medical cannabis. We are the first to produce and sell medical cannabis to Virginians thanks to every member of our team.”
Merida Capital Partners is the largest investor in Dharma Pharmaceuticals. Mitch Baruchowitz, Kevin Gibbs and Colin Kelley of Merida Capital Partners have provided critical infrastructure and operational guidance to launch the operation. While Dharma was the last company to go live in Virginia, it is the first to produce and sell medicine to patients. This is a direct result of Merida’s operational team, whose track record in launching limited-license medical cultivation operations is one of the longest in the industry. Members of the Merida team have successfully secured cultivation, processing and dispensary licenses in highly regulated U.S. states including Connecticut, Minnesota, Pennsylvania, Missouri, Maryland and West Virginia.
Gibbs says, “The Dharma Pharmaceuticals team has been an amazing partner of ours. We worked relentlessly this year with Shanna, Jack and Michael to launch this company and bring medicine to Virginia. We look forward to helping patients throughout the Commonwealth get safe access to medical cannabis.”
Dharma Pharmaceuticals is currently located in the Bristol Mall at 500 Gate City Hwy, Suite 460, Bristol, VA. Products sold will include inhalation devices, ingestibles, sprays, oils, suppositories and others. For more information on products, how to become a patient, and their COVID-19 restrictions, go to www.dharmacann.com.
About Dharma Pharmaceuticals
Dharma Pharmaceuticals is one of four licensed medical cannabis companies in the Commonwealth of Virginia. Based in Bristol, Virginia, Dharma is committed to bringing high quality cannabis oil products to Virginia’s patients. With deep ties to Southwestern Virginia, Dharma looks forward to working with doctors across Virginia to provide medical cannabis to Virginians seeking safe and effective plant-based medicines. For more information go to www.dharmacann.com.
About Merida Capital Partners
Merida Capital Partners is a private equity firm targeting fundamental growth drivers which accelerate the rapid development of the cannabis and hemp industries. Merida’s motto, Responsible Investing in the Cannabis Ecosystem, highlights its focus on governance while identifying leading cultivation technologies, products and services associated with the evolution of cannabis and hemp as agricultural products, plant-based medicines, constituents in pharmaceutical formulations and recreational consumer products. For more information, please visit www.meridacap.com or follow Merida on twitter @meridacap.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.